Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced fluctuations, with a current price of 37.85 yuan per share and a market capitalization of 16.105 billion yuan, despite a significant year-to-date increase of 155.90% [1] - The company has seen a net outflow of main funds amounting to 30.06 thousand yuan, with large orders showing a buy of 829.73 thousand yuan and a sell of 737.58 thousand yuan [1] - 泰恩康's main business revenue composition includes 65.16% from pharmaceutical agency, 31.70% from pharmaceutical manufacturing, and 2.97% from pharmaceutical technology services and technology transfer [1] Group 2 - As of June 30, 泰恩康 had 10,900 shareholders, a decrease of 33.05% from the previous period, with an average of 27,747 circulating shares per person, an increase of 49.36% [2] - For the first half of 2025, 泰恩康 reported operating revenue of 34.7 million yuan, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.08 million yuan, down 56.75% year-on-year [2] - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3]
泰恩康跌2.04%，成交额5241.77万元，主力资金净流出30.06万元